Empiriko, Interchim Partner on Mass Spec-based Drug Metabolism Research | GenomeWeb

NEW YORK (GenomeWeb News) – Empiriko will use Interchim's mass spectrometry-based technology to perform drug metabolism studies as part of a partnership between the companies announced today.

Under the terms of the deal, Empiriko will leverage Interchim's PuriFlash MassSpec technology to perform near real-time and cost-effective in vitro and ex vivo studies using Empiriko's Biomimiks technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.